For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 1,680,375 | 1,219,846* | 1,912,829 | 1,583,521 |
| Research and development | 1,724,872 | 3,256,098* | 2,436,971 | 3,068,379 |
| Total operating expenses | 3,405,247 | 4,475,944 | 4,349,800 | 4,651,900 |
| Loss from operations | -3,405,247 | -4,475,944* | -4,349,800 | -4,651,900 |
| Interest income | 42,160 | 114,432* | 100,921 | 114,745 |
| Other income, net | 33,916 | 4,731* | 71,456 | 206,140 |
| Net loss | -3,329,171 | -4,356,781 | -4,177,423 | -4,331,015 |
| Basic EPS | -0.3 | -0.393 | -0.39 | -0.4 |
| Diluted EPS | -0.3 | -0.393 | -0.39 | -0.4 |
| Basic Average Shares | 11,253,030 | 11,076,407 | 10,833,393 | 10,784,725 |
| Diluted Average Shares | 11,253,030 | 11,076,407 | 10,833,393 | 10,784,725 |
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)